Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

(2019) Marta Alvarez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks

(2019) Rima K. Acosta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection

(2019) Juan Ambrosioni et al.   AIDS

Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States

(2019) Emily P Hyle et al.   CLINICAL INFECTIOUS DISEASES

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

(2018) Charlotte Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor

(2018) C Spertilli Raffaelli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa

(2018) Seth C Inzaule et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

(2018) Ingeborg E A Wijting et al.   JOURNAL OF INFECTIOUS DISEASES

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

(2018) Maureen Oliveira et al.   Retrovirology

Two cases of dolutegravir failure with R263K mutation

(2018) Margarida Cardoso et al.   AIDS

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses

(2018) Andrea Hauser et al.   PLoS One

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance

(2018) N Ahmed et al.   Open Forum Infectious Diseases

Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance

(2017) Marc Noguera-Julian et al.   JOURNAL OF INFECTIOUS DISEASES

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Deep sequencing for HIV-1 clinical management

(2017) Maria Casadellà et al.   VIRUS RESEARCH

Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom

(2016) A Tostevin et al.   HIV MEDICINE

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection

(2016) J. Ambrosioni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial

(2015) Rami Kantor et al.   CLINICAL INFECTIOUS DISEASES

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

(2015) L. Marije Hofstra et al.   CLINICAL INFECTIOUS DISEASES

Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences

(2015) José Ramón Santos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.

(2015) M. Casadellà et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

(2015) Kaitlin Anstett et al.   JOURNAL OF VIROLOGY

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity

(2014) T. Mesplede et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

(2014) Jonathan Z. Li et al.   PLoS One

Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy

(2014) Richard M. Gibson et al.   PLoS One

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing

(2012) Daniele Armenia et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Fast gapped-read alignment with Bowtie 2

(2012) Ben Langmead et al.   NATURE METHODS

Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy

(2011) Benjamin Young et al.   ANTIVIRAL THERAPY

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

(2011) Sarita D Boyd et al.   ANTIVIRAL THERAPY

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

(2011) Linda Wittkop et al.   LANCET INFECTIOUS DISEASES

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study

(2011) Raph L Hamers et al.   LANCET INFECTIOUS DISEASES

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors

(2010) Charlotte Charpentier et al.   AIDS

Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment

(2010) Jia Liu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY